OpenAI's AI Reportedly Solves Millennium Prize Navier-Stokes Problem, Marking a Major Scientific Breakthrough

Rapid advancements in artificial intelligence, while offering significant scientific benefits, also raise concerns about ethical development, control, and societal impact, as highlighted by calls for a slowdown in AI progress. New medical treatments are promising but remain in clinical development.

📌 Key developments

• AI Solves Navier-Stokes Problem OpenAI's latest artificial intelligence (AI) model has reportedly solved the Navier-Stokes problem, one of the long-standing Millennium Prize Problems, which describes the complex motion of viscous fluids like water or air. This achievement, detailed in various reports, involved the AI system autonomously tackling a puzzle that has eluded human mathematicians for decades. This matters because it demonstrates a significant leap in AI's ability to solve extremely complex mathematical and scientific challenges, potentially accelerating discoveries in fields like engineering and climate modeling. However, this is a lab-based achievement by an AI, and the ethical implications of how such powerful AI is developed and credited are still being debated; it does not yet prove that AI can independently generate novel mathematical theories or that the methods used are always transparent and fair.
• New Lung Cancer Treatment Shows Positive Survival Akeso, Inc. announced positive overall survival (OS) results from its randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study for ivonescimab (AK112-303), a first-in-class next-generation immuno-oncology therapy, as a first-line treatment for patients with PD-L1-positive (Programmed Death-Ligand 1 positive, meaning the cancer cells express a protein that helps them evade the immune system) locally advanced or metastatic non-small cell lung cancer (NSCLC). Immuno-oncology therapies work by harnessing the body's own immune system to fight cancer. This is significant for lung cancer patients, a condition widely feared, offering a potential new targeted therapy that showed a 27% reduction in the risk of death in the intention-to-treat (ITT) population, with a median OS of 30.8 months. This drug is in late-stage clinical development (Phase III) and is still some years away from widespread availability, pending regulatory approvals. It does not yet prove universal efficacy for all lung cancer types or patients, and long-term side effects are still being monitored.
• Another Lung Cancer Drug Improves Survival in Relapsed Cases Hansoh Pharma presented interim analysis results from its Phase 3 ARTEMIS-008 study for risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate (ADC), showing a statistically significant and clinically meaningful improvement in overall survival (OS) for patients with relapsed small cell lung cancer (SCLC) following failure of platinum-based therapy. An antibody-drug conjugate (ADC) is a targeted therapy that combines an antibody, which specifically recognizes cancer cells, with a potent chemotherapy drug. This is important for patients with SCLC, a highly aggressive form of lung cancer, offering a new treatment option for those whose initial therapies have failed. This drug is in late-stage clinical development (Phase III) and has received Breakthrough Therapy Designation and Orphan Drug Designation in multiple regions, but is still years away from general availability. It does not yet prove a cure or universal effectiveness, and further data on long-term outcomes and safety will be crucial.
• Strength Training Linked to Slower Brain Aging A new study published in GeroScience suggests that resistance training, also known as strength training, can slow biological brain aging by up to 2.3 years. Researchers analyzed 309 older adults over one year, finding that both moderate and heavy resistance training significantly reduced biological brain age compared to a non-exercise control group. This matters because it provides further evidence for accessible lifestyle interventions that can positively impact longevity and cognitive health, particularly relevant for conditions like Alzheimer's and dementia, which are widely feared. This is a preliminary finding from a one-year study and does not yet prove that strength training can prevent specific neurodegenerative diseases or that the observed brain age reduction translates directly to a longer cognitive lifespan for every individual. More long-term and larger studies are needed.
• AI Identifies Potential New Side Effects of GLP-1 Drugs A University of Pennsylvania team, in a study published in Nature Health, used artificial intelligence (AI) to analyze over 400,000 Reddit posts from users of popular GLP-1 (glucagon-like peptide-1) receptor agonist drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. The AI identified unexpected symptoms, including changes in menstrual cycles, chills, hot flashes, and fatigue, that may not be fully represented in clinical trials or official regulatory information. GLP-1 receptor agonists are medications that help regulate blood sugar and suppress appetite, used for type 2 diabetes and weight loss, conditions widely prevalent and feared. This matters because it demonstrates a novel approach to pharmacovigilance (the science of monitoring the safety of medicines) and could uncover previously overlooked patient experiences, potentially leading to a more complete understanding of these widely used drugs. However, this AI analysis identifies patterns in self-reported data and does not prove that these medications directly cause these symptoms; further clinical research is needed to establish causality and prevalence.
• AI Leaders Call for Pacing Development Dario Amodei, CEO of Anthropic, a leading artificial intelligence company, called for a slowdown in the development of advanced AI systems, proposing a three-step plan for safety and alignment that includes third-party evaluations, industry-wide coordination, and global cooperation. This call was quickly supported by other prominent AI figures, including Sam Altman, CEO of OpenAI, and Elon Musk, CEO of xAI. This matters because it highlights growing concerns among top developers about the rapid advancement and potential risks of uncontrolled artificial intelligence, signaling a shift towards prioritizing safety and ethical considerations alongside technological progress. It does not yet prove that such a slowdown will be effectively implemented or that all AI developers will adhere to these calls, as regulatory frameworks are still nascent.
• Naturally Occurring Carbon Nanotubes Discovered on Moon Scientists have published a paper detailing the discovery of naturally occurring single-walled carbon nanotubes (ultra-thin hollow cylinders made from a single layer of carbon atoms) and graphitic carbon in samples brought back from the far side of the Moon. While carbon nanotubes are often associated with artificial preparation on Earth, this finding suggests they can form naturally in space. This matters because it expands our understanding of lunar geology and the natural formation of complex carbon structures in extraterrestrial environments, which could have implications for future materials science and astrobiology. It does not yet prove the existence of extraterrestrial life or 'alien tech,' as the paper notes the assumption is these are naturally occurring.

💡 Why it matters

These developments could accelerate scientific discovery, offer new hope for patients with challenging diseases like lung cancer, and initiate crucial discussions on the ethical governance of rapidly evolving AI technologies, impacting global health and technological policy.

🎭 People in the news

• Dario Amodei — CEO of Anthropic, called for a slowdown in AI development.
• Sam Altman — CEO of OpenAI, supported Amodei's call for AI pacing.
• Elon Musk — CEO of xAI, supported Amodei's call for AI pacing.
• Professor Caicun Zhou — Principal Investigator of HARMONi-2, IASLC President, will present full results for ivonescimab.
• Sharath Chandra Guntuku — Research Associate Professor at University of Pennsylvania School of Engineering and Applied Science, led the AI study on GLP-1 side effects.

👀 What to watch

• Further details from the full oral presentation of the HARMONi-2 study for ivonescimab at the World Conference on Lung Cancer on September 15.
• Discussions and potential policy responses following the call from AI leaders for a slowdown in advanced AI development.
• Additional clinical research to confirm causality and prevalence of potential new side effects of GLP-1 drugs identified by AI analysis.